Literature DB >> 19572049

Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia.

Matthew Klimek1, Shan Wang, Adeleye Ogunkanmi.   

Abstract

Red yeast rice is a Chinese fermented rice product (Monascus purpureus) that some have claimed improves blood circulation by decreasing cholesterol and triglyceride levels in humans. The supplement contains naturally occurring monacolin K, the active ingredient found in Merck's prescription agent lovastatin (Mevacor). Lovastatin is associated with various adverse effects such as myopathy and abnormal liver function test results, which can lead to serious problems if patients are not monitored and treated. The inclusion of lovastatin in red yeast rice and the lack of dietary supplement regulation by the FDA raise safety concerns for health care professionals as well as for patients. Studies have shown that red yeast rice products can be beneficial in lowering serum cholesterol levels, but they are not without risk. Furthermore, product uniformity, purity, labeling, and safety cannot be guaranteed.

Entities:  

Keywords:  Monascus purpureus; dietary supplement; hyperlipidemia; lovastatin; myopathy; red yeast rice

Year:  2009        PMID: 19572049      PMCID: PMC2697909     

Source DB:  PubMed          Journal:  P T        ISSN: 1052-1372


  15 in total

1.  Chinese red rice-induced myopathy.

Authors:  Dena James Smith; Kenneth E Olive
Journal:  South Med J       Date:  2003-12       Impact factor: 0.954

2.  FDA rejects sale of over the counter statins.

Authors:  Owen Dyer
Journal:  BMJ       Date:  2005-01-22

3.  Symptomatic myopathy due to red yeast rice.

Authors:  Paul S Mueller
Journal:  Ann Intern Med       Date:  2006-09-19       Impact factor: 25.391

4.  An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents.

Authors:  D Heber; A Lembertas; Q Y Lu; S Bowerman; V L Go
Journal:  J Altern Complement Med       Date:  2001-04       Impact factor: 2.579

5.  Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient.

Authors:  G V Ramesh Prasad; Timothy Wong; Galo Meliton; Salma Bhaloo
Journal:  Transplantation       Date:  2002-10-27       Impact factor: 4.939

6.  Long-term trends in the use of complementary and alternative medical therapies in the United States.

Authors:  R C Kessler; R B Davis; D F Foster; M I Van Rompay; E E Walters; S A Wilkey; T J Kaptchuk; D M Eisenberg
Journal:  Ann Intern Med       Date:  2001-08-21       Impact factor: 25.391

7.  Effects of the mycotoxin citrinin on micronucleus formation in a cytokinesis-block genotoxicity assay in cultured human lymphocytes.

Authors:  Hamiyet Dönmez-Altuntas; Gülcan Dumlupinar; Nalan Imamoglu; Zuhal Hamurcu; Bilal Cem Liman
Journal:  J Appl Toxicol       Date:  2007 Jul-Aug       Impact factor: 3.446

8.  Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey.

Authors:  D M Eisenberg; R B Davis; S L Ettner; S Appel; S Wilkey; M Van Rompay; R C Kessler
Journal:  JAMA       Date:  1998-11-11       Impact factor: 56.272

9.  Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia.

Authors:  Osama Gheith; Hussein Sheashaa; Mohamed Abdelsalam; Zaki Shoeir; Mohamed Sobh
Journal:  Clin Exp Nephrol       Date:  2008-03-26       Impact factor: 2.801

10.  Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials.

Authors:  Jianping Liu; Jing Zhang; Yi Shi; Sameline Grimsgaard; Terje Alraek; Vinjar Fønnebø
Journal:  Chin Med       Date:  2006-11-23       Impact factor: 5.455

View more
  29 in total

Review 1.  Red yeast rice for the treatment of dyslipidemia.

Authors:  Frances M Burke
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

2.  Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study.

Authors:  Emmanuel Barrat; Yassine Zaïr; Pascal Sirvent; Patrice Chauveau; Corinne Maudet; Béatrice Housez; Elodie Derbord; Jean-François Lescuyer; Jean-Marie Bard; Murielle Cazaubiel; Sébastien L Peltier
Journal:  Eur J Nutr       Date:  2012-12-25       Impact factor: 5.614

3.  Isoflavones enhance pharmacokinetic exposure of active lovastatin acid via the upregulation of carboxylesterase in high-fat diet mice after oral administration of Xuezhikang capsules.

Authors:  Dong Feng; Chun Ge; Zhao-Yi Tan; Jian-Guo Sun; Yuan Xie; Lan Yao; Cai-Xia Yan; Ji-Ye Aa; Guang-Ji Wang
Journal:  Acta Pharmacol Sin       Date:  2018-06-19       Impact factor: 6.150

4.  Isoflavones and phytosterols contained in Xuezhikang capsules modulate cholesterol homeostasis in high-fat diet mice.

Authors:  Dong Feng; Jian-guo Sun; Run-bin Sun; Bing-chen Ou-Yang; Lan Yao; Ji-ye Aa; Fang Zhou; Jing-wei Zhang; Jian Zhang; Guang-ji Wang
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

Review 5.  Functional food red yeast rice (RYR) for metabolic syndrome amelioration: a review on pros and cons.

Authors:  Seema Patel
Journal:  World J Microbiol Biotechnol       Date:  2016-04-02       Impact factor: 3.312

Review 6.  Immune-Mediated Necrotizing Myopathy.

Authors:  Iago Pinal-Fernandez; Maria Casal-Dominguez; Andrew L Mammen
Journal:  Curr Rheumatol Rep       Date:  2018-03-26       Impact factor: 4.592

7.  Peripheral neuropathy induced by red yeast rice in a patient with a known small bowel gastrointestinal tumour.

Authors:  Sonia Kumari; Jennifer M Sherriff; David Spooner; Robert Beckett
Journal:  BMJ Case Rep       Date:  2013-04-05

Review 8.  Evidence of lifestyle modification in the management of hypercholesterolemia.

Authors:  G S Mannu; M J S Zaman; A Gupta; H U Rehman; P K Myint
Journal:  Curr Cardiol Rev       Date:  2013-02-01

9.  Study of the effects of monacolin k and other constituents of red yeast rice on obesity, insulin-resistance, hyperlipidemia, and nonalcoholic steatohepatitis using a mouse model of metabolic syndrome.

Authors:  Makoto Fujimoto; Koichi Tsuneyama; Shao-Yuan Chen; Takeshi Nishida; Jiun-Liang Chen; Yen-Chen Chen; Takako Fujimoto; Johji Imura; Yutaka Shimada
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-20       Impact factor: 2.629

10.  Complementary and alternative medicine and cardiovascular disease: an evidence-based review.

Authors:  Matthew J Rabito; Alan David Kaye
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-22       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.